Skip to Main Content

Paper Details

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
J Immunother Cancer
20
2021
Author NameAffiliation
Manish A Shah
Manish A ShahNewYork-Presbyterian Hospital/Weill Cornell Medical Center
  • 1 - 2

Datasets

Release 1.2